George C. Tsokos, MD, is a Professor of Medicine at Harvard Medical School and Chief of Rheumatology and Clinical Immunology at Beth Israel Deaconess Medical Center. Dr Tsokos has served as President of the Clinical Immunology Society, on the boards of directors for the American College of Rheumatology and the Lupus Foundation of America, member/chair of multiple federal study sections, and editor/member of the editorial boards for top scientific journals. He has received several awards, including a MERIT from NIH, the Lee C. Howley Sr. Prize, the Evelyn V. Hess, the Distinguished Basic Investigator Award from the American College of Rheumatology, the Lupus Insight Prize from the Lupus Research Alliance, and the Carol Nachman Prize for Rheumatology. He is a Master of the American College of Physicians and the American College of Rheumatology, a member of American Association of Physicians and Fellow of AAAS.

• Part I - Epidemiology and diagnosis1. Introduction2. The patient3. Practicing law with lupus: the story of a patient4. Epidemiology5. Measuring disease activity6. Disease development and outcome7. Socioeconomic aspects of SLE8. Biomarkers in systemic lupus erythematosus9. Biomarkers in lupus nephritisPart II - Pathogenesis10. Overview of the pathogenesis of systemic lupus erythematosus11. System lupus erythematosus and the environment12. Genes and genetics in human SLE13. Monogenic lupus14. Hormones15. Clinical aspects of the complement system in systemic lupus erythematosus16. T cells17. B cells in SLE18. Neutrophils in systemic lupus erythematosus19. The role of dendritic cells in systemic lupus erythematosus20. Platelets in lupus21. Cytokines22. RNA/DNA sensing in SLE—Toll-like receptors and beyond23. The role of interferons in systemic lupus erythematosus24. Fcγ receptors in autoimmunity and end organ damage25. Apoptosis, autophagy, and necrosis26. Infections in early systemic lupus erythematosus pathogenesis27. Microbiota influences on systemic lupus erythematosus and Sjögren’s syndrome28. Origin of autoantibodies29. Anti-DNA antibodies30. Antihistone and antispliceosome antibodies31. Immune complexes in systemic lupus erythematosus32. MicroRNA in systemic lupus erythematosus33. Metabolic control of lupus pathogenesis34. Epigenetics35. What do mouse models and genetics teach us about human SLE?Part III - Mechanisms of tissue damage36. Mechanisms of renal damage in systemic lupus erythematosus37. Mechanisms of vascular damage in systemic lupus erythematosus38. The mechanism of skin damage39. Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosusPart IV - Clinical aspects of the disease40. Constitutional symptoms and fatigue in systemic lupus erythematosus41. The musculoskeletal system in SLE42. Cutaneous lupus erythematosus43. The clinical evaluation of kidney disease in systemic lupus erythematosus44. The pathology of lupus nephritis45. Cardiovascular disease in systemic lupus erythematosus: an update46. The lung in systemic lupus erythematosus47. Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus48. Systemic lupus erythematosus and infections49. Malignancies in systemic lupus erythematosus50. The nervous system in systemic lupus erythematosus51. Psychiatric lupus52. Overlap syndromes53. Systemic lupus erythematosus and the eye54. Fertility and pregnancy in systemic lupus erythematosus55. Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment56. Incomplete lupus syndromes57. Lupus in children and adolescents58. Drug-induced lupus59. Vasculitis in lupus60. Accrual of organ damage in lupusPart V - Antiphospholipid Syndrome61. Pathogenesis of antiphospholipid syndrome62. Antibodies and diagnostic tests in antiphospholipid syndrome63. Clinical manifestationsPart VI - Treatment64. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus65. Value of antimalarial drugs in the treatment of lupus,66. Systemic glucocorticoids67. Cytotoxic drug treatment68. Treatment of antiphospholipid syndrome69. New treatments of systemic lupus erythematosus70. Cell therapies in lupus

Select Guide Rating

George C. Tsokos, MD, is a Professor of Medicine at Harvard Medical School and Chief of Rheumatology and Clinical Immunology at Beth Israel Deaconess Medical Center. Dr Tsokos has served as President of the Clinical Immunology Society, on the boards of directors for the American College of Rheumatology and the Lupus Foundation of America, member/chair of multiple federal study sections, and editor/member of the editorial boards for top scientific journals. He has received several awards, including a MERIT from NIH, the Lee C. Howley Sr. Prize, the Evelyn V. Hess, the Distinguished Basic Investigator Award from the American College of Rheumatology, the Lupus Insight Prize from the Lupus Research Alliance, and the Carol Nachman Prize for Rheumatology. He is a Master of the American College of Physicians and the American College of Rheumatology, a member of American Association of Physicians and Fellow of AAAS.

• Part I - Epidemiology and diagnosis1. Introduction2. The patient3. Practicing law with lupus: the story of a patient4. Epidemiology5. Measuring disease activity6. Disease development and outcome7. Socioeconomic aspects of SLE8. Biomarkers in systemic lupus erythematosus9. Biomarkers in lupus nephritisPart II - Pathogenesis10. Overview of the pathogenesis of systemic lupus erythematosus11. System lupus erythematosus and the environment12. Genes and genetics in human SLE13. Monogenic lupus14. Hormones15. Clinical aspects of the complement system in systemic lupus erythematosus16. T cells17. B cells in SLE18. Neutrophils in systemic lupus erythematosus19. The role of dendritic cells in systemic lupus erythematosus20. Platelets in lupus21. Cytokines22. RNA/DNA sensing in SLE—Toll-like receptors and beyond23. The role of interferons in systemic lupus erythematosus24. Fcγ receptors in autoimmunity and end organ damage25. Apoptosis, autophagy, and necrosis26. Infections in early systemic lupus erythematosus pathogenesis27. Microbiota influences on systemic lupus erythematosus and Sjögren’s syndrome28. Origin of autoantibodies29. Anti-DNA antibodies30. Antihistone and antispliceosome antibodies31. Immune complexes in systemic lupus erythematosus32. MicroRNA in systemic lupus erythematosus33. Metabolic control of lupus pathogenesis34. Epigenetics35. What do mouse models and genetics teach us about human SLE?Part III - Mechanisms of tissue damage36. Mechanisms of renal damage in systemic lupus erythematosus37. Mechanisms of vascular damage in systemic lupus erythematosus38. The mechanism of skin damage39. Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosusPart IV - Clinical aspects of the disease40. Constitutional symptoms and fatigue in systemic lupus erythematosus41. The musculoskeletal system in SLE42. Cutaneous lupus erythematosus43. The clinical evaluation of kidney disease in systemic lupus erythematosus44. The pathology of lupus nephritis45. Cardiovascular disease in systemic lupus erythematosus: an update46. The lung in systemic lupus erythematosus47. Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus48. Systemic lupus erythematosus and infections49. Malignancies in systemic lupus erythematosus50. The nervous system in systemic lupus erythematosus51. Psychiatric lupus52. Overlap syndromes53. Systemic lupus erythematosus and the eye54. Fertility and pregnancy in systemic lupus erythematosus55. Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment56. Incomplete lupus syndromes57. Lupus in children and adolescents58. Drug-induced lupus59. Vasculitis in lupus60. Accrual of organ damage in lupusPart V - Antiphospholipid Syndrome61. Pathogenesis of antiphospholipid syndrome62. Antibodies and diagnostic tests in antiphospholipid syndrome63. Clinical manifestationsPart VI - Treatment64. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus65. Value of antimalarial drugs in the treatment of lupus,66. Systemic glucocorticoids67. Cytotoxic drug treatment68. Treatment of antiphospholipid syndrome69. New treatments of systemic lupus erythematosus70. Cell therapies in lupus

Select Guide Rating

George C. Tsokos, MD, is a Professor of Medicine at Harvard Medical School and Chief of Rheumatology and Clinical Immunology at Beth Israel Deaconess Medical Center. Dr Tsokos has served as President of the Clinical Immunology Society, on the boards of directors for the American College of Rheumatology and the Lupus Foundation of America, member/chair of multiple federal study sections, and editor/member of the editorial boards for top scientific journals. He has received several awards, including a MERIT from NIH, the Lee C. Howley Sr. Prize, the Evelyn V. Hess, the Distinguished Basic Investigator Award from the American College of Rheumatology, the Lupus Insight Prize from the Lupus Research Alliance, and the Carol Nachman Prize for Rheumatology. He is a Master of the American College of Physicians and the American College of Rheumatology, a member of American Association of Physicians and Fellow of AAAS.

• Part I - Epidemiology and diagnosis1. Introduction2. The patient3. Practicing law with lupus: the story of a patient4. Epidemiology5. Measuring disease activity6. Disease development and outcome7. Socioeconomic aspects of SLE8. Biomarkers in systemic lupus erythematosus9. Biomarkers in lupus nephritisPart II - Pathogenesis10. Overview of the pathogenesis of systemic lupus erythematosus11. System lupus erythematosus and the environment12. Genes and genetics in human SLE13. Monogenic lupus14. Hormones15. Clinical aspects of the complement system in systemic lupus erythematosus16. T cells17. B cells in SLE18. Neutrophils in systemic lupus erythematosus19. The role of dendritic cells in systemic lupus erythematosus20. Platelets in lupus21. Cytokines22. RNA/DNA sensing in SLE—Toll-like receptors and beyond23. The role of interferons in systemic lupus erythematosus24. Fcγ receptors in autoimmunity and end organ damage25. Apoptosis, autophagy, and necrosis26. Infections in early systemic lupus erythematosus pathogenesis27. Microbiota influences on systemic lupus erythematosus and Sjögren’s syndrome28. Origin of autoantibodies29. Anti-DNA antibodies30. Antihistone and antispliceosome antibodies31. Immune complexes in systemic lupus erythematosus32. MicroRNA in systemic lupus erythematosus33. Metabolic control of lupus pathogenesis34. Epigenetics35. What do mouse models and genetics teach us about human SLE?Part III - Mechanisms of tissue damage36. Mechanisms of renal damage in systemic lupus erythematosus37. Mechanisms of vascular damage in systemic lupus erythematosus38. The mechanism of skin damage39. Pathogenesis of tissue injury in the brain in patients with systemic lupus erythematosusPart IV - Clinical aspects of the disease40. Constitutional symptoms and fatigue in systemic lupus erythematosus41. The musculoskeletal system in SLE42. Cutaneous lupus erythematosus43. The clinical evaluation of kidney disease in systemic lupus erythematosus44. The pathology of lupus nephritis45. Cardiovascular disease in systemic lupus erythematosus: an update46. The lung in systemic lupus erythematosus47. Gastrointestinal, hepatic, and pancreatic disorders in systemic lupus erythematosus48. Systemic lupus erythematosus and infections49. Malignancies in systemic lupus erythematosus50. The nervous system in systemic lupus erythematosus51. Psychiatric lupus52. Overlap syndromes53. Systemic lupus erythematosus and the eye54. Fertility and pregnancy in systemic lupus erythematosus55. Neonatal lupus: Clinical spectrum, biomarkers, pathogenesis, and approach to treatment56. Incomplete lupus syndromes57. Lupus in children and adolescents58. Drug-induced lupus59. Vasculitis in lupus60. Accrual of organ damage in lupusPart V - Antiphospholipid Syndrome61. Pathogenesis of antiphospholipid syndrome62. Antibodies and diagnostic tests in antiphospholipid syndrome63. Clinical manifestationsPart VI - Treatment64. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus65. Value of antimalarial drugs in the treatment of lupus,66. Systemic glucocorticoids67. Cytotoxic drug treatment68. Treatment of antiphospholipid syndrome69. New treatments of systemic lupus erythematosus70. Cell therapies in lupus

Select Guide Rating